Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Multiple adjusted Cox proportional hazards model for analysis of drug discontinuation of a first TNF inhibitor in different BMI categories

From: Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis

Variable HR 95% CI p
Obese (ref: normal BMI) 1.01 0.63–1.65 0.95
Overweight (ref: normal BMI) 0.98 0.79–1.38 0.92
Age 1.00 0.98–1.01 0.73
HLA-B27 positivity 0.86 0.60–1.25 0.43
Male sex 0.68 0.49–0.96 0.03
nr-axSpA (ref: AS) 1.47 1.01–2.14 0.04
Current smoking yes vs. no 0.92 0.66–1.28 0.61
Exercise yes vs. no 0.82 0.60–1.12 0.21
BASDAI 1.04 0.96–1.13 0.35
BASMI 1.07 0.97–1.18 0.17
Elevated CRP 0.71 0.51–0.98 0.04
Enthesitis 0.91 0.64–1.30 0.61
DMARDs 0.56 0.34–0.93 0.02
NSAIDs 1.00 0.55–1.83 0.99
  1. Analysis performed in 343 patients
  2. AS Ankylosing Spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASMI Bath Ankylosing Spondylitis Mobility Index, BMI body mass index, CI confidence interval, CRP C-reactive peptide, DMARDs disease-modifying antirheumatic drugs, HLA-B27 human leucocyte antigen-B27, HR hazard ratio, nr-axSpA nonradiographic axial spondyloarthritis. NSAIDs nonsteroidal anti-inflammatory drugs, ref reference, TNF tumor necrosis factor